首页> 外文期刊>Scientific reports. >Synergistically enhanced selective intracellular uptake of anticancer drug carrier comprising folic acid-conjugated hydrogels containing magnetite nanoparticles
【24h】

Synergistically enhanced selective intracellular uptake of anticancer drug carrier comprising folic acid-conjugated hydrogels containing magnetite nanoparticles

机译:协同增强的抗癌药物载体的选择性细胞内摄取,包括含有磁铁矿纳米粒子的叶酸 - 缀合水凝胶

获取原文
           

摘要

Targeted drug delivery has long been extensively researched since drug delivery and release at the diseased site with minimum dosage realizes the effective therapy without adverse side effects. In this work, to achieve enhanced intracellular uptake of anticancer drug carriers for efficient chemo-therapy, we have designed targeted multifunctional anticancer drug carrier hydrogels. Temperature-responsive poly(N-isopropylacrylamide) (PNIPAm) hydrogel core containing superparamagnetic magnetite nanoparticles (MNP) were prepared using precipitation polymerization, and further polymerized with amine-functionalized copolymer shell to facilitate the conjugation of targeting ligand. Then, folic acid, specific targeting ligand for cervical cancer cell line (HeLa), was conjugated on the hydrogel surface, yielding the ligand conjugated hybrid hydrogels. We revealed that enhanced intracellular uptake by HeLa cells in vitro was enabled by both magnetic attraction and receptor-mediated endocytosis, which were contributed by MNP and folic acid, respectively. Furthermore, site-specific uptake of the developed carrier was confirmed by incubating with several other cell lines. Based on synergistically enhanced intracellular uptake, efficient cytotoxicity and apoptotic activity of HeLa cells incubated with anticancer drug loaded hybrid hydrogels were successfully achieved. The developed dual-targeted hybrid hydrogels are expected to provide a platform for the next generation intelligent drug delivery systems.
机译:靶向药物递送长期被广泛研究,因为患药物的药物递送和患有最小剂量的药物递送和释放意识到没有不良副作用的有效治疗。在这项工作中,为了实现增强的抗癌药物载体的细胞内摄取,用于高效化疗治疗,我们设计了靶向多功能抗癌药物载体水凝胶。使用沉淀聚合制备温度响应的聚(N-异丙基丙烯酰胺)(丙蛋白)水凝胶核(MNP),并用胺官能化共聚物壳进一步聚合,以促进靶向配体的缀合。然后,叶酸,宫颈癌细胞系(HELA)的特异性靶向配体在水凝胶表面上缀合,得到配体缀合的杂交水凝胶。我们透露,通过磁吸引力和受体介导的内吞作用,通过MNP和叶酸的助剂介导的磁吸引力和受体介导的内吞作用,增强了Hela细胞的细胞内摄取。此外,通过与其他几种细胞系孵育来确认发育载体的特异性摄取。基于协同增强的细胞内摄取,成功达到了与抗癌药物负载杂交水凝胶孵育的HeLa细胞的有效细胞毒性和凋亡活性。预期开发的双靶向混合水凝胶是为下一代智能药物递送系统提供的平台。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号